What is Gastroparesis Drugs Market?
Gastroparesis is a disease of the muscles of the stomach or the nerves controlling the muscles that affect the normal spontaneous movement of the muscles (motility). This condition results into inadequate grinding of food by the stomach, and poor emptying of food from the stomach into the intestine. This condition is generally treated with nutritional support, drugs that stimulate the muscle to work, drugs for treating nausea and vomiting, and, less often, electrical pacing, and surgery.
The market study is being classified by Type (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injection and Other), by Application (Diabetic Gastroparesis, Idiopathic Gastroparesis and Post-Surgical Gastroparesis) and major geographies with country level break-up.
Allergan, Plc. (Ireland), Abbott Laboratories (Abbott Arzneimittel GmbH) (United States), AstraZeneca Plc. (United Kingdom), Cadila Pharmaceuticals Ltd. (India), GlaxoSmithKline Plc. (United Kingdom), Neurogastrx, Inc. (United States), Valeant Pharmaceuticals International, Inc. (Canada), Theravance Biopharma (United Kingdom) and Johnson & Johnson (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ETX Pharma, Inc. (United States) and Evoke Pharma (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gastroparesis Drugs market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Gastroparesis Drugs market by Type, Application and Region.
On the basis of geography, the market of Gastroparesis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of DIabetes among People
- Rise in the Number of Surgeries Performed Worldwide
- Technological Advancements in the Medical Science
- Side Effects of the Gastroparesis Drugs
- Growth in the Geriatric Population Worldwide
- Growing Healthcare Sector Worldwide
- Time-consuming Regulatory Process
Key Target AudienceGastroparesis Drugs Manufacturers, Raw Material Suppliers', Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase